Pharmaceutical Investing Coherus BioSciences Announces Positive Topline 24-Week Treatment Phase Three Results for CHS-1420 (HUMIRA® Biosimilar Candidate) in Patients with Psoriasis
Cellceutix Reports 24 Core Phase 2b Clinical Trial Sites for Oral Prurisol Treatment of Moderate-To-Severe Psoriasis
UCB and Dermira Announce Second CIMZIA® Phase 3 Trial Meets Co-Primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
Momenta Pharmaceuticals Announces Positive Top-Line Phase 3 Results for M923, a Proposed HUMIRA® Biosimilar
CIMZIA® Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
Exicure Announces Dosing of First Patient in Phase 1 Trial for the Treatment of Chronic Plaque Psoriasis
